Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer

Active Publication Date: 2012-08-09
CAPITALBIO CORP +1
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0022]In another aspect, the present invention provides a method of prognosis for survival for an individual having cervical cancer or cervical dysplasia, which method comprises: a) determining the level of miRNA expression in the sample using a system comprising a plurality of probes, wherein at least about 50% of the probes are capable of detecting an miRNA having a nucleotide sequence that is set forth in SEQ ID NO:1-20 or their corresponding homologues; and b) comparing the level of miRNA expression with a reference level, wherein a characteristic change in the level of miRNA expression indicates a high or low rate of survival for the individual. In some embodiments, the method further comprises determin

Problems solved by technology

Although HPV is capable of initiating cancer through the disruption of multiple tumor-suppressor pathways, alone it is not sufficient for the development of the fully transformed cancer phenotype (Burk, 1999).
Currently, no method is available to distinguish progressive CIN from that destined to regress.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer
  • Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer
  • Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Samples and Analysis of miRNA Levels by Using miRNA Microarray

[0191]Patients and Samples

[0192]Five pairs of cervical cancer tissues and corresponding normal cervical tissues were used. These specimens were obtained from patients in The First Teaching Hospital of Xinjing Medical University from 2006 to 2008 with informed consent and agreement. All tissue samples were from untreated patients undergoing surgery, and they were formalin-fixed paraffin-embedded (FFPE) until the extraction of miRNA. The tumor cell concentrations were evaluated and tumor histology was confirmed by a pathologist. The study was approved by the medical-ethics committee of The First Teaching Hospital of Xinjing Medical University.

[0193]Fabrication of the miRNA Microarray

[0194]Altogether 509 mature miRNA sequences were assembled and integrated into our miRNA microarray design, which comprised 435 human (including a further 122 predicted miRNA sequences from published references (Xie et al., 2005),...

example 2

Discrimination between hsa-miR-133a and hsa-miR-133b by RT-PCR

[0202]The results of Example 1 showed that the expression levels of hsa-miR-133a and hsa-miR-133b were up-regulated in cervical carcinomas. As shown in Table 1, mammalian hsa-miR-133 has two mature isoforms, hsa-miR-133a and hsa-miR-133b, which differ at a single 3′-terminal base, although the pre-miR-133a and -133b sequences are more different. Specific primers have been designed according to the pre-miR-133a and -133b sequences and used for discrimination of these two isoforms. The pre-miR-133a and -133b sequences can be downloaded from the following website: http: / / microrna.sanger.ac.uk / (Griffths-Jones, et al., Nucleic Acids Research (2006) Vol. 34, Database issue).

[0203]Primers used for the amplification of pre-hsa-miR-133a and pre-hsa-miR-133b are listed in Table 2. Total RNA from 6 normal cervical tissues and 6 cervical carcinomas were purified as described in Example 1. The reverse transcription (RT) reaction cont...

example 3

Analysis of miRNA Levels by RT-PCR

[0205]Total cellular RNAs were prepared from FFPE tissues as described in Example 1. Reverse transcriptase reaction (10 μl) contained 10 ng of total RNA, 2 μl of RT primer (Exiqon, Vedbaek, Denmark), 1× RT buffer, 0.2 mM each of dNTPs, 0.5 μl of reverse transcriptase and 0.5 μl of RNase inhibitor. The reactions were incubated in an MJ Research PTC-225 Thermocycler for 30 min at 50° C., 5 min at 85° C. and then held at 4° C. All reverse transcriptase reactions, including no-template controls, were run in duplicate. The RT-PCR employed a mercury LNA™ microRNA PCR System kit (Exiqon) and a LightCycler (Roche Diagnostics, Mannheim, Germany) following the manufacturer's protocols. The PCR reaction (20 μl) included 4 μl of 10× diluted RT product, 10 μl of SYBR® Green master mix (Exiqon), 1 μl of LNA™ PCR primer and 1 μl of Universal PCR primer (Exiqon). The reactions were incubated at 95° C. for 10 min, followed by 60 cycles of 95° C. for 10 s, 60° C. for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Lengthaaaaaaaaaa
Login to view more

Abstract

The invention provides methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer. The methods comprise the step of determining the expression levels or genetic status of specific miRNAs.

Description

TECHNICAL FIELD[0001]This application pertains to systems and methods for diagnosis of disease (such as cervical dysplasia and cervical cancer), prognosis and improvement of patient survival based on the expression level of microRNAs.BACKGROUND ART[0002]Uterine cervical cancer is the second most common cancer among women worldwide, with nearly 500,000 new cases per year (Parkin et al., 2005). It caused an estimated 274,000 deaths in the year 2002 and it is one of the leading causes of cancer-related deaths in young women (zur Hausen, 2002). Cervical cancer typically results from cellular transformation after persistent infections with high-risk type human papilloma virus (HPV) (Scheffner et al., 1990). Almost all squamous cell carcinomas and the majority of adenocarcinomas of the stratified epithelium are HPV positive. Although HPV is capable of initiating cancer through the disruption of multiple tumor-suppressor pathways, alone it is not sufficient for the development of the fully...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/713C07H21/02G01N33/53C40B40/06C40B30/04C12Q1/68C07H21/04A61P35/00
CPCC12Q1/6886C12Q2600/118C12Q2600/178C12Q2600/158C12Q2600/136A61P35/00
Inventor QIN, WENYANDONG, PENGDENG, TUOMA, CAILINGMITCHELSON, KEITH RICHARDWEN, HAOCHENG, JING
Owner CAPITALBIO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap